Abstract

BACKGROUND

Hydroxyurea and blood transfusion therapies remain the main therapeutic strategies for Sickle cell disease. Preliminary data suggest substantial variation and inconsistencies in practice of these two therapeutic modalities in South Asia. In this systematic review we searched Medline, Cochrane library and Scopus for articles on usage of hydroxyurea and blood transfusion therapies for sickle cell disease in South Asia published in English between October 2005 and October 2020.

RESULTS

We selected 41 papers: 33 from India, 3 from Sri Lanka, 2 each from Pakistan and Bangladesh and one from Nepal. Only 14 prospective trials focused on hydroxyurea therapy from which majority (n = 10; 71.4%) adopted fixed low dose (10 mg/kg/day) regimen. With hydroxyurea therapy, 12 and 9 studies reported significant reductions in vaso-occlusive crises and transfusion requirement respectively. Severe anaemia (haemoglobin level < 6-7 g/dl) was the commonest indicator (n = 8) for transfusion therapy followed by vaso-occlusive crisis.

CONCLUSIONS

Published data on the hydroxyurea and transfusion therapies in South Asia are limited and heterogeneous. A clear gap of knowledge exists about the nature of the sickle cell disease in the Indian subcontinent particularly from countries outside India necessitating further evidence-based assessments and interventions.

MeSH

Cells, Blood Transfusion, Blood, Anemia, Sickle Cell, Rare Diseases, Therapeutics, Neglected Diseases, Hydroxyurea, Vaso-Occlusive Crises

Cited by

• Treatment Options That Reduce the Duration of Sickle Cell Vaso-Occlusive Crises: A Systematic Review. Cureus, 2022
• Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa. Semin Hematol, 2024
• Blood Transfusion Vs. Hydroxyurea for Stroke Prevention in Children With Sickle Cell Anemia: A Systematic Review and Meta-Analysis. Cureus, 2022
• A retrospective research of adverse event reporting system events for voxelotor based on the FAERS database. BMC Pharmacol Toxicol, 2025
• Sickle cell disease: More than a century of progress. Where do we stand now? Indian J Med Res, 2021
• Sickle Cell Disease Update: New Treatments and Challenging Nutritional Interventions. Nutrients, 2024
• Sickle cell health awareness, perspectives and experiences (SHAPE) survey: perspectives on sickle cell disease (SCD) from healthcare providers in India, Malaysia, and Thailand. Orphanet J Rare Dis, 2025